The felicities of health capital

Les félicités du capital en santé

Catherine Bourgain (), Maurice Cassier (), Jean-Paul Gaudillière and Pierre-André Juven
Additional contact information
Catherine Bourgain: CERMES3 - UMR 8211 / U988 / UM 7 - CERMES3 - Centre de recherche Médecine, sciences, santé, santé mentale, société - EHESS - École des hautes études en sciences sociales - INSERM - Institut National de la Santé et de la Recherche Médicale - CNRS - Centre National de la Recherche Scientifique - UPCité - Université Paris Cité
Maurice Cassier: CERMES3 - UMR 8211 / U988 / UM 7 - CERMES3 - Centre de recherche Médecine, sciences, santé, santé mentale, société - EHESS - École des hautes études en sciences sociales - INSERM - Institut National de la Santé et de la Recherche Médicale - CNRS - Centre National de la Recherche Scientifique - UPCité - Université Paris Cité
Jean-Paul Gaudillière: CERMES3 - UMR 8211 / U988 / UM 7 - CERMES3 - Centre de recherche Médecine, sciences, santé, santé mentale, société - EHESS - École des hautes études en sciences sociales - INSERM - Institut National de la Santé et de la Recherche Médicale - CNRS - Centre National de la Recherche Scientifique - UPCité - Université Paris Cité
Pierre-André Juven: CERMES3 - UMR 8211 / U988 / UM 7 - CERMES3 - Centre de recherche Médecine, sciences, santé, santé mentale, société - EHESS - École des hautes études en sciences sociales - INSERM - Institut National de la Santé et de la Recherche Médicale - CNRS - Centre National de la Recherche Scientifique - UPCité - Université Paris Cité

Post-Print from HAL

Abstract: While the term "crisis" has constantly been used since the mid-2000s to describe a financialized pharmaceutical industry speculating on a limited number of innovations of high clinical added value, this article broadens the perspective by considering the pharmaceutical capitalism of the Global North and South in all its diversity. We present a socio-historical analysis of several modes of implementation of these health industries and the felicity conditions of their scientific and financial model. While stressing the importance of the political infrastructures underpinning the construction of markets, and the institutional orders within which the industries exist (and which they help to shape), we show that it is possible to analyse the development of pharmaceutical capitalism in terms of three criteria: the degree of financialization, the forms of intellectual property, and the role of biotechnologies. This analysis calls into question the division between the industrial and innovative North, on the one hand, and the South that has to manage shortages, on the other.

Keywords: Pharmaceutical industry; financialisation; patent; traditional knowledge; crisis; regulation; North(s); South(s); Industrie pharmaceutique; financiarisation; brevet; savoirs traditionnels; Crise; régulation; Nord(s); Sud(s) (search for similar items in EconPapers)
Date: 2021
Note: View the original document on HAL open archive server: https://shs.hal.science/halshs-03464016
References: Add references at CitEc
Citations:

Published in Revue Française de Socio-Economie, 2021, La santé, miroir des sociétés, 26, pp.127-147. ⟨10.3917/rfse.026.0127⟩

Downloads: (external link)
https://shs.hal.science/halshs-03464016/document (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:hal:journl:halshs-03464016

DOI: 10.3917/rfse.026.0127

Access Statistics for this paper

More papers in Post-Print from HAL
Bibliographic data for series maintained by CCSD ().